{"id":17222,"date":"2024-01-15T18:00:00","date_gmt":"2024-01-15T17:00:00","guid":{"rendered":"https:\/\/www.sequanamedical.com\/?p=17222"},"modified":"2024-01-18T09:59:38","modified_gmt":"2024-01-18T08:59:38","slug":"transparency-notifications-from-shareholders-9","status":"publish","type":"post","link":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/transparency-notifications-from-shareholders-9\/","title":{"rendered":"Transparency Notifications from Shareholders"},"content":{"rendered":"\n

PRESS RELEASE<\/strong><\/p>\n\n\n\n

Regulated information<\/strong><\/p>\n\n\n\n

15 January 2024, 06:00 pm CET<\/p>\n\n\n\n

Ghent, Belgium \u2013 15 January 2024 \u2013 <\/strong>Sequana Medical NV (Euronext Brussels: SEQUA) <\/strong>(the “Company<\/strong>” or “Sequana<\/strong> Medical<\/strong>“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the shareholders listed below, notifying the number of voting rights attached to shares mentioned next to their respective names in the table below.<\/p>\n\n\n\n

 <\/td>Reason for notification<\/strong><\/td>Number of shares and voting rights held<\/strong><\/td><\/tr>
Number<\/strong><\/td>% of total outstanding shares<\/strong>(1)<\/sup><\/strong><\/td><\/tr>
Soci\u00e9t\u00e9 F\u00e9d\u00e9rale de Participations et d’Investissement SA – Federale Participatie- en Investeringsmaatschappij NV \/ Belfius Insurance SA (2)<\/sup><\/td>Disposal of voting securities or voting rights<\/td>2,803,199<\/td>9.93%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

_____________<\/p>\n\n\n\n

Notes:<\/p>\n\n\n\n